Recent Quotes (30 days)

You have no recent quotes
chg | %

Biocon Ltd  

(Public, BOM:532523)   Watch this stock  
Find more results for BOM: 532523
+30.25 (5.61%)
Jan 19 - Close
BOM real-time data - Disclaimer
Currency in INR
Range 545.35 - 575.30
52 week 295.00 - 575.30
Open 548.00
Vol. 871,801.00
Mkt cap 341.48B
P/E 75.44
Div/yield 1.00/0.18
EPS 7.55
Shares 600.00M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin 9.20% 17.55%
Operating margin 9.16% 17.97%
EBITD margin - 25.04%
Return on average assets 3.77% 7.71%
Return on average equity 5.60% 13.80%
Employees 4,832 -
CDP Score - -


20th KM, Hosur Road, Electronics City
+91-80-28082808 (Phone)
+91-80-28523423 (Fax)

Website links


Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Officers and directors

Kiran Mazumdar-Shaw Executive Non-Independent Chairman of the Board, Managing Director
Age: 64
Arun Suresh Chandavarkar Ph.D. Chief Executive Officer, Joint Managing Director, Executive Director
Age: 53
Siddharth Mittal Chief Financial Officer
Peter James Jonathan Bains CEO & Director of Syngene
Age: 58
Abhijit Barve M.D. Ph.D. President - Research & Development
Ravi Limaye President - Marketing
Amitava Saha Senior Vice President - Human Resources
Rajiv Balakrishnan Compliance Officer, Company Secretary
Catherine Rosenberg Director of Syngene
Age: 54
John Mccallum Marshall Shaw Non-Executive Vice Chairman of the Board
Age: 68